NASDAQ:ABUS Arbutus Biopharma (ABUS) Stock Price, News & Analysis → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Free ABUS Stock Alerts $2.72 -0.03 (-1.09%) (As of 04:31 PM ET) Add Compare Share Share Today's Range$2.68▼$2.7550-Day Range$2.49▼$3.1252-Week Range$1.69▼$3.29Volume317,967 shsAverage Volume1.25 million shsMarket Capitalization$488.22 millionP/E RatioN/ADividend YieldN/APrice Target$4.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Arbutus Biopharma alerts: Email Address Arbutus Biopharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside58.7% Upside$4.33 Price TargetShort InterestHealthy2.88% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.39) to ($0.43) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.24 out of 5 starsMedical Sector745th out of 907 stocksPharmaceutical Preparations Industry345th out of 422 stocks 3.5 Analyst's Opinion Consensus RatingArbutus Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageArbutus Biopharma has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.88% of the outstanding shares of Arbutus Biopharma have been sold short.Short Interest Ratio / Days to CoverArbutus Biopharma has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Arbutus Biopharma has recently increased by 13.63%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldArbutus Biopharma does not currently pay a dividend.Dividend GrowthArbutus Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ABUS. Previous Next 1.1 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Arbutus Biopharma this week, compared to 2 articles on an average week.Search Interest9 people have searched for ABUS on MarketBeat in the last 30 days. This is an increase of 350% compared to the previous 30 days.MarketBeat Follows5 people have added Arbutus Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arbutus Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.40% of the stock of Arbutus Biopharma is held by insiders.Percentage Held by Institutions43.79% of the stock of Arbutus Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Arbutus Biopharma are expected to decrease in the coming year, from ($0.39) to ($0.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arbutus Biopharma is -6.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arbutus Biopharma is -6.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArbutus Biopharma has a P/B Ratio of 4.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About Arbutus Biopharma Stock (NASDAQ:ABUS)Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.Read More ABUS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ABUS Stock News HeadlinesApril 25, 2024 | americanbankingnews.comArbutus Biopharma (ABUS) to Release Earnings on ThursdayApril 21, 2024 | msn.comArbutus Biopharma Sets Date for Q1 2024 Financial ResultsApril 25, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.April 18, 2024 | globenewswire.comArbutus to Report First Quarter 2024 Financial Results and Provide Corporate UpdateApril 16, 2024 | americanbankingnews.comArbutus Biopharma Co. (NASDAQ:ABUS) Short Interest Up 10.2% in MarchApril 10, 2024 | seekingalpha.comArbutus Biopharma: The Markman Win Is A Good Milestone But Uncertainty RemainsApril 4, 2024 | msn.comArbutus Vs. Moderna Patent Dispute Over Covid-19 Vaccine Gets Response From JudgeApril 4, 2024 | markets.businessinsider.comArbutus Biopharma Reports Claim Construction Ruling In Patent Infringement Lawsuit Against ModernaApril 25, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.April 4, 2024 | globenewswire.comArbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against ModernaApril 3, 2024 | seekingalpha.comArbutus Biopharma jumps after claim construction order in patent fight with ModernaApril 1, 2024 | finance.yahoo.comIs Arbutus Biopharma (NASDAQ:ABUS) In A Good Position To Deliver On Growth Plans?March 19, 2024 | finance.yahoo.comABUS Jan 2025 7.000 callMarch 12, 2024 | msn.comArbutus Biopharma to Participate in Prominent Investor ConferencesMarch 8, 2024 | globenewswire.comArbutus to Participate in Two Upcoming Investor ConferencesMarch 3, 2024 | finance.yahoo.comArbutus Biopharma Corporation (NASDAQ:ABUS) Consensus Forecasts Have Become A Little Darker Since Its Latest ReportMarch 2, 2024 | finance.yahoo.comAnalysts Just Made A Major Revision To Their Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenue ForecastsMarch 1, 2024 | finance.yahoo.comArbutus Biopharma Corporation (NASDAQ:ABUS) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Arbutus Biopharma on Strong Clinical Outlook and Litigation ProspectsMarch 1, 2024 | finance.yahoo.comQ4 2023 Arbutus Biopharma Corp Earnings CallFebruary 29, 2024 | finanznachrichten.deArbutus Biopharma Corporation: Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate UpdateFebruary 29, 2024 | finance.yahoo.comArbutus Biopharma Corp (ABUS) Reports Year-End Financial Results and Progress in Clinical TrialsFebruary 29, 2024 | globenewswire.comArbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate UpdateFebruary 28, 2024 | finance.yahoo.comABUS Jun 2024 3.000 putFebruary 27, 2024 | finance.yahoo.comABUS Apr 2024 6.000 callFebruary 23, 2024 | finance.yahoo.comABUS Apr 2024 3.000 callFebruary 23, 2024 | finance.yahoo.comABUS Sep 2024 3.000 callSee More Headlines Receive ABUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today4/25/2024Next Earnings (Confirmed)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ABUS CUSIPN/A CIK1447028 Webwww.arbutusbio.com Phone(267) 469-0914Fax604-419-3201Employees73Year Founded1992Price Target and Rating Average Stock Price Target$4.33 High Stock Price Target$5.00 Low Stock Price Target$4.00 Potential Upside/Downside+59.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-72,850,000.00 Net Margins-401.57% Pretax Margin-401.57% Return on Equity-57.82% Return on Assets-43.42% Debt Debt-to-Equity RatioN/A Current Ratio5.87 Quick Ratio5.87 Sales & Book Value Annual Sales$18.14 million Price / Sales26.91 Cash FlowN/A Price / Cash FlowN/A Book Value$0.63 per share Price / Book4.32Miscellaneous Outstanding Shares179,492,000Free Float169,799,000Market Cap$488.22 million OptionableOptionable Beta2.03 Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Michael J. McElhaugh (Age 49)Co-Founder, Interim President, CEO & Director Comp: $606.62kDr. Michael J. Sofia Ph.D. (Age 66)Chief Scientific Officer Comp: $628.43kMr. David C. Hastings CPA (Age 63)CFO & Chief Accounting Officer Comp: $647.1kMs. Lisa M. CaperelliVice President of Investor RelationsMr. J. Christopher Naftzger BA (Age 57)Esq., J.D., General Counsel, Chief Compliance Officer & Secretary Ms. Shannon Briscoe SPHRVice President of Human ResourcesDr. Karen Sims M.D. (Age 53)Ph.D., Chief Medical Officer Mr. R. Hector Mackay-Dunn B.A. (Age 73)J.D., L.L.B., Q.C., Corporate Secretary More ExecutivesKey CompetitorsOculisNASDAQ:OCSCOMPASS PathwaysNASDAQ:CMPSAnaptysBioNASDAQ:ANABKalVista PharmaceuticalsNASDAQ:KALVApplied TherapeuticsNASDAQ:APLTView All CompetitorsInstitutional OwnershipPremier Path Wealth Partners LLCBought 8,300 shares on 4/24/2024Ownership: 0.017%PFG Investments LLCBought 19,200 shares on 4/22/2024Ownership: 0.011%FourWorld Capital Management LLCSold 251,056 shares on 2/15/2024Ownership: 0.650%Cowen AND Company LLCBought 50,000 shares on 2/8/2024Ownership: 0.030%BNP Paribas Financial MarketsBought 49,745 shares on 2/7/2024Ownership: 0.174%View All Institutional Transactions ABUS Stock Analysis - Frequently Asked Questions Should I buy or sell Arbutus Biopharma stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ABUS shares. View ABUS analyst ratings or view top-rated stocks. What is Arbutus Biopharma's stock price target for 2024? 3 equities research analysts have issued 12 month price objectives for Arbutus Biopharma's stock. Their ABUS share price targets range from $4.00 to $5.00. On average, they predict the company's share price to reach $4.33 in the next twelve months. This suggests a possible upside of 58.7% from the stock's current price. View analysts price targets for ABUS or view top-rated stocks among Wall Street analysts. How have ABUS shares performed in 2024? Arbutus Biopharma's stock was trading at $2.50 at the start of the year. Since then, ABUS stock has increased by 9.2% and is now trading at $2.73. View the best growth stocks for 2024 here. Are investors shorting Arbutus Biopharma? Arbutus Biopharma saw a increase in short interest in March. As of March 31st, there was short interest totaling 4,550,000 shares, an increase of 10.2% from the March 15th total of 4,130,000 shares. Based on an average daily volume of 1,320,000 shares, the days-to-cover ratio is currently 3.4 days. View Arbutus Biopharma's Short Interest. When is Arbutus Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our ABUS earnings forecast. How can I listen to Arbutus Biopharma's earnings call? Arbutus Biopharma will be holding an earnings conference call on Thursday, May 2nd at 8:45 AM Eastern. Interested parties can register for or listen to the call using this link. How were Arbutus Biopharma's earnings last quarter? Arbutus Biopharma Co. (NASDAQ:ABUS) released its quarterly earnings data on Thursday, February, 29th. The biopharmaceutical company reported ($0.12) EPS for the quarter, meeting analysts' consensus estimates of ($0.12). The biopharmaceutical company earned $2.15 million during the quarter, compared to analysts' expectations of $4.74 million. Arbutus Biopharma had a negative net margin of 401.57% and a negative trailing twelve-month return on equity of 57.82%. During the same quarter in the prior year, the firm earned ($0.14) earnings per share. What ETFs hold Arbutus Biopharma's stock? ETFs with the largest weight of Arbutus Biopharma (NASDAQ:ABUS) stock in their portfolio include Morningstar US Small Growth (MSGR) and Amplify Treatments, Testing and Advancements ETF (GERM).Invesco Nasdaq Future Gen 200 ETF (QQQS). What is Mark J. Murray's approval rating as Arbutus Biopharma's CEO? 6 employees have rated Arbutus Biopharma Chief Executive Officer Mark J. Murray on Glassdoor.com. Mark J. Murray has an approval rating of 22% among the company's employees. This puts Mark J. Murray in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Arbutus Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Companies (BHC), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), GW Pharmaceuticals (GWPH), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), TherapeuticsMD (TXMD) and Novavax (NVAX). Who are Arbutus Biopharma's major shareholders? Arbutus Biopharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include Premier Path Wealth Partners LLC (0.02%) and PFG Investments LLC (0.01%). View institutional ownership trends. How do I buy shares of Arbutus Biopharma? Shares of ABUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ABUS) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThese AI trades triggered this morning (545% return)Prosper Trading Academytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressFed launches fourth dollar overhaulStansberry ResearchThe AI stock to buy right nowStockEarningsExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arbutus Biopharma Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
